Pelage Pharmaceuticals just pulled off what most in biotech only whisper about, a $120M Series B round that doesn’t just fund science, it fuels a movement. Co-led by ARCH Venture Partners and GV, with continued backing from Main Street Advisors, Visionary Ventures, and YK Bioventures, this Los Angeles-based regenerative medicine company is proving that the future of hair restoration isn’t cosmetic, it’s cellular. The kind of cellular that comes from knowing exactly which metabolic switch in a stem cell decides whether your hair grows or ghosts you.
Founded in 2018 by UCLA heavyweights William Lowry, Heather Christofk, and Michael Jung, Pelage was built on a decade of research that cracked one of biology’s coolest codes: hair follicle stem cells have a unique metabolic gear. Flip that gear, and dormant follicles wake up. No hormones. No side effects. Just science turning the lights back on. Under CEO Daniel Gil, Ph.D., and CMO Christina Weng, M.D., the team has turned that discovery into PP405, a topical small molecule that reactivates dormant stem cells by inhibiting the mitochondrial pyruvate carrier, basically reprogramming cellular metabolism to restart growth from the root up.
The Phase 2a trial didn’t just check boxes; it hit milestones. 78 participants, zero systemic absorption, no adverse events, and results that raised eyebrows across dermatology: at Week 8, 31% of men with advanced hair loss saw >20% density growth vs. 0% on placebo. That’s faster than any existing treatment, proof that Pelage isn’t chasing regrowth; it’s regenerating from scratch.
With $150.75M now raised across all rounds, Pelage is gearing up for Phase 3 in 2026, pushing PP405 toward the first FDA-approved regenerative therapy for androgenetic alopecia. And they’re not stopping there. The same platform could target chemotherapy-induced and stress-related hair loss, conditions where innovation’s been on pause for decades.
Board Chair Cathy Friedman from GV and new board member Richard Heyman, Ph.D., from ARCH bring heavyweight biotech firepower to the table. Together with Daniel Gil and his lean but lethal team, they’re out to prove that hair loss can be treated with the precision of molecular medicine, not the guesswork of yesterday’s playbook.
